Table 1.
Clinical, pathologic, and laboratory data from patients with COVID19-associated nephropathy (n = 43)
| Clinical parameter | Value |
|---|---|
| Age (mean ± SD; range) | 52.8 ± 11.8; 30–78 yr |
| Sex | 22/43 male, 21/43 female |
| Severity of COVID-19 (n = 33) | 3 outpatients, 17 hospitalized, 13 required ICU care |
| Patient comorbidities | HTN 33 Pts, Smoking 2 Pts, Obesity 26 Pts, Diabetes 12 Pts |
| Patients with CKD at time of biopsy | 19 (44%) |
| Patients with CKD at follow up | 40 of 42 (1 deceased) (95%) |
| Biopsy indication | 39/43 AKI + proteinuria; 4/43 proteinuria without AKI |
| Days between COVID and biopsy (mean ± SD) | 15.4 ± 23.2 |
| Days between biopsy and follow-up (mean ± SD) | 244 ± 143 |
| Patients on dialysis at time of biopsy | 16 (37%) |
| Patients on dialysis at follow-up | 14 (8 were on dialysis at time of biopsy) (33%) |
| Patients with kidney transplant at follow-up | 0 |
| Deceased patients | 1 |
| Laboratory parameter | Value |
| Creatinine at time of biopsy (mean ± SD; mg/dl); n = 41 | 7.0 ± 4.7 |
| Creatinine at follow-up (mean ± SD; mg/dl); n = 28a | 3.1 ± 1.9 |
| Change in creatinine at follow-up (mean ± SD; mg/dl) | −3.1 ± 5.1, P = 0.0002 (Wilcoxon Signed Rank) |
| Proteinuria at time of biopsy (mean ± SD; g/day), n = 26 | 12.2 ± 10.9 |
| Proteinuria at follow-up (mean ± SD; g/day); n = 23a | 2.4 ± 2.7 |
| Change in proteinuria at follow up (mean ± SD; g/day) | −7.01 ± 10.4, P = 0.00001 (Wilcoxon Signed Rank) |
| Albumin at time of biopsy (mean ± SD; g/dl), n = 25 | 2.4 ± 0.6 |
| Albumin at follow-up (mean ± SD; g/dl), n = 15 | 3.7 ± 0.5 |
AKI, acute kidney disease; CKD, chronic kidney disease; HTN, hypertension; ICU, intensive care unit; Pts, pateints.
a
Patients on dialysis excluded from analysis, as follow-up creatinine and proteinuria measurements would not be accurate.